IMAX IMAX CORP

Q3 2025 10-Q

Filed: Oct 23, 2025Period ending Sep 30, 2025

Health Care

Photographic Equipment & SuppliesSEC EDGAR

IMAX CORP (IMAX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 23, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Management expects sufficient capital and liquidity for operating needs next 12 months
• No off-balance sheet arrangements likely to materially affect financial condition

+1 more insights

Risk Factors

• Newly added trade policy risk due to recent U.S. tariffs and retaliatory measures by China and Canada impacting costs and cash flows
• Updated geopolitical risk emphasizing uncertainty in global trade relations and potential adverse effects on box office receipts and consumer discretionary income

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$107M

▲ +16.6% YoY▲ +16.3% QoQ

Net Income

$21M

▲ +48.7% YoY▲ +83.5% QoQ

Gross Margin

63.1%

▲ +729bp YoY▲ +461bp QoQ

Operating Margin

27.2%

▲ +601bp YoY▲ +1159bp QoQ

Net Margin

19.4%

▲ +417bp YoY▲ +709bp QoQ

ROE

5.9%

Total Assets

$890M

EPS (Diluted)

$0.37

▲ +42.3% YoY▲ +76.2% QoQ

Operating Cash Flow

$68M

▲ +91.4% YoY▲ +190.6% QoQ

Source: XBRL data from IMAX CORP Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on IMAX CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.